ReviewEuropean respiratory review : an official journal of the European Respiratory Society2015
Malignant pleural mesothelioma: history, controversy and future of a manmade epidemic.
Review in European respiratory review : an official journal of the European Respiratory Society, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06886672 (Genetic Susceptibility in MAlignant Pleural Mesothelioma), which is not on this map. Cited by 88 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Genetic Susceptibility in MAlignant Pleural Mesothelioma: Clinical Implication of GermliNE variaTionS
Who cites it
88 citing papers in PubMed, 2 syntheses or guidelines pooled it, 183 citations in OpenAlex.
- Cancer Incidence and Mortality among Petroleum Industry Workers and Residents Living in Oil Producing Communities: A Systematic Review and Meta-Analysis.International journal of environmental research and public health · 2021Pooled it
- Pretreatment elevated serum lactate dehydrogenase as a significant prognostic factor in malignant mesothelioma: A meta-analysis.Medicine · 2016Pooled it
- A Validated Clinical Risk Prediction Model for Lung Cancer in Smokers of All Ages and Exposure Types: A HUNT Study.EBioMedicine · 2018Trial
- Economic Impact of Asbestos in Colombia: Estimation of the Direct and Societal Costs of Lung Cancer and Mesothelioma in 2022.International journal of environmental research and public health · 2026Article
- Macrophages bend long fibres with flexural rigidity lower than 3 mN·nmParticle and fibre toxicology · 2026Article
- Genetic variability ofRadiology and oncology · 2025Article
- Epidemiological Trends in Mesothelioma Mortality in Colombia (1997-2022): A Retrospective National Study.International journal of environmental research and public health · 2025Article
- Air pollution and its impact on cancer incidence, cancer care and cancer outcomes.BMJ oncology · 2025Review
- Therapeutic Strategies to Improve the Treatment of Pleural Mesothelioma.Current medicinal chemistry · 2025Review
- Advances in diagnosis and management of pleural mesothelioma: the Danish clinical guidelines.European clinical respiratory journal · 2025Review
- Mesothelioma diagnosis-still a challenge.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2024Article
- Asbestos ban policies and mesothelioma mortality in Greece.BMC public health · 2024Article
- Article
- BAP1, Wilms' tumor 1, and calretinin in predicting survival and response to first-line chemotherapy in patients with pleural mesothelioma.Journal of cancer research and clinical oncology · 2024Article
- Pleural Fluid-to-Blood BNP Ratio May Contribute to Prognosis in Malignant Pleural Mesothelioma.Clinics and practice · 2023Article
- Article
- Highlighting the immunohistochemical differences of malignant mesothelioma subtypes via case presentations.Thoracic cancer · 2023Review
- A study of somaticPleura and peritoneum · 2023Article
- MEK1 drives oncogenic signaling and interacts with PARP1 for genomic and metabolic homeostasis in malignant pleural mesothelioma.Cell death discovery · 2023Article
- The Genes-Stemness-Secretome Interplay in Malignant Pleural Mesothelioma: Molecular Dynamics and Clinical Hints.International journal of molecular sciences · 2023Review
28 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Asbestos is the term for a family of naturally occurring minerals that have been used on a small scale since ancient times. Industrialisation demanded increased mining and refining in the 20th century, and in 1960, Wagner, Sleggs and Marchand from South Africa linked asbestos to mesothelioma, paving the way to the current knowledge of the aetiology, epidemiology and biology of malignant pleural mesothelioma. Pleural mesothelioma is one of the most lethal cancers, with increasing incidence worldwide. This review will give some snapshots of the history of pleural mesothelioma discovery, and the body of epidemiological and biological research, including some of the controversies and unresolved questions. Translational research is currently unravelling novel circulating biomarkers for earlier diagnosis and novel treatment targets. Current breakthrough discoveries of clinically promising noninvasive biomarkers, such as the 13-protein signature, microRNAs and the BAP1 mesothelioma/cancer syndrome, are highlighted. The asbestos history is a lesson to not be repeated, but here we also review recent in vivo and in vitro studies showing that manmade carbon nanofibres could pose a similar danger to human health. This should be taken seriously by regulatory bodies to ensure thorough testing of novel materials before release in the society.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.